Lentiviral Gene Therapy: Retrovirus Vectors Explained

Added:

核心优势
载体构建
三代演进
自毁设计
质粒系统
实验流程
技术总结

核心优势

0:00
Playing Section
  • 1

    逆转录病毒可将自身基因组整合至宿主细胞DNA中,这是其应用于基因治疗的核心优势。

  • 2

    病毒基因组主要包含gag、pol和env三大类基因,分别编码结构蛋白、酶和包膜蛋白。

  • 3

    野生型病毒存在致病性,必须通过基因工程改造,剔除毒性部分后才能安全用于治疗。

The basic structure and life cycle of viruses, particularly how retroviruses replicate using reverse transcription to convert RNA into DNA.
The Central Dogma of Molecular Biology, specifically understanding DNA replication, transcription, translation, and how foreign genetic material integrates into a host genome.
Fundamental concepts of gene therapy, including the difference between treating symptoms and correcting genetic mutations at the DNA level.
Basic recombinant DNA technology, such as the use of plasmids, promoter sequences, and restriction enzymes to manipulate genetic material.
Safety mechanisms in vector design, such as self-inactivating (SIN) vectors and the prevention of replication-competent retroviruses (RCR).
Real-world clinical applications of lentiviral vectors, specifically ex vivo gene therapies like CAR-T cell therapy for cancer and treatments for severe combined immunodeficiency (SCID).
The risk of insertional mutagenesis, exploring how viral integration can accidentally activate oncogenes or disrupt essential host genes.
A comparative analysis of gene delivery vehicles, contrasting retroviruses and lentiviruses with Adeno-Associated Viruses (AAV) and non-viral delivery methods like lipid nanoparticles.
56.3K views480likes32:05@shomusbiologyofficialOriginal Release: 2013-12-09

Lentiviral vectors, derived from retroviruses, are powerful tools for gene therapy because they can integrate their genetic material into the host cell genome and transduce both dividing and non-dividing cells; these vectors are constructed by deleting pathogenic genes (such as env, vpr, vpu, nef, and tat) from the HIV genome while retaining essential structural genes (gag, pol, rev) and using co-transfection of multiple plasmids (transfer plasmid carrying the gene of interest, packaging plasmid providing structural proteins, and envelope plasmid providing VSV-G envelope) to produce replication-deficient viral particles that safely deliver therapeutic genes to target cells.